Purpose: The purpose of this research was to determine inter-and intrapatient differences in the pharmacokinetic profiles of etoposide and its genotoxic catechol metabolite during conventional multiple-day dosing of etoposide in pediatric patients.
INTRODUCTION
Etoposide (scheme 1) is a semisynthetic epipodophyllotoxin analog that has been used since the 1980s as a highly efficacious anticancer drug for the treatment of many different adult and pediatric solid tumors and leukemias (1) . However, introduction of epipodophyllotoxins into clinical usage led to the recognition of a form of secondary leukemia characterized by balanced chromosomal translocations as a treatment complication (2-5). The overall incidence of leukemia after epipodophyllotoxin-containing regimens is approximately 2-3% (6), but the incidence has been higher with intermittent weekly or twice weekly scheduling (7) and with more intensive treatments (8) . When the National Cancer Institute Cancer Therapy Evaluation Program monitored the occurrence of leukemia in 12 clinical trails using low (Ͻ1500 mg/m 2 ), moderate (1500 -2999 mg/m 2 ), or high (Ͼ3000 mg/m 2 ) epipodophyllotoxin cumulative doses, the lack of a dose-response effect suggested that factors other than cumulative dose of the parent drug are the primary determinants of risk (6) .
One of the major pathways of etoposide metabolism involves O-demethylation to etoposide catechol by cytochrome P450 3A4 (CYP 3A4; Fig. 1 ; Refs. 9, 10). The promoter region of the CYP3A4 gene is polymorphic. We have reported previously that the wild-type CYP3A4 genotype increases and the variant CYP3A4 genotype decreases the risk of epipodophyllotoxin-related leukemias with translocation of the MLL gene at chromosome band 11q23 (11) . Etoposide catechol can undergo sequential one-electron oxidation steps to etoposide semiquinone and etoposide quinone (12, 13) . The quinone metabolite is a Michael acceptor, which could damage cells through alkylation of crucial cellular macromolecules including DNA and proteins (12) (13) (14) (15) (16) (17) . In addition, subsequent redox cycling initialized by etoposide catechol can result in the formation of reactive oxygen species (14) . Reactive oxygen species can either damage DNA directly (18) or initiate lipid peroxidation. The resulting lipid hydroperoxides can then undergo homolytic decomposition to form DNA-reactive aldehydic bifunctional electrophiles, such as malondialdehyde, 4-hydroxy-2-nonenal, and 4-oxo-2-nonenal (19) . Thus, etoposide metabolites as well as the parent drug are genotoxins.
The primary mechanism of cytotoxicity of etoposide and the basis for its antineoplastic action involves DNA topoisomerase II-mediated chromosomal breakage that initiates apoptosis (20 -22) . It has been suggested that the same mechanism of DNA damage may lead to translocations (5) . However, the O-demethylated metabolites of etoposide have cytotoxic properties that are as potent as the parent drug (17) . These etoposide metabolites like the parent drug increase the formation of DNA topoisomerase II cleavage complexes (23, 24) , and can damage MLL and its partner genes by enhancing DNA topoisomerase II cleavage (25, 26) .
The anticancer activity of etoposide has been demonstrated to be schedule-dependent (27) . Despite several studies conducted in adults and children on the efficacy and safety of different schedules of etoposide, the optimal schedule has not been determined (28, 29) . On the basis of the observation that five consecutive daily 2-h infusions of 100 mg/m 2 resulted in etoposide concentrations above 1 g/ml for a significantly longer time (96.5 h) than a 500 mg/m 2 continuous infusion over 24-h (46 h), common schedules for etoposide treatment involve multiple-day dosing (30) . However, multiple-day dosing could be harmful if plasma concentrations of etoposide and/or its genotoxic metabolites increase during the course of treatment.
We reported previously the simultaneous analysis of etoposide and its catechol metabolite as protein-free and total concentrations in plasma samples from pediatric patients using liquid chromatography/tandem mass spectrometry methodology (31) . The purpose of the present study was to elaborate a pharmacokinetic model for etoposide and its catechol metabolite during a conventional multiple-day schedule that is often used in children. The model was developed to determine specific rate constants for individual compartments and to provide a mathematical description of individual pathways that are involved in etoposide disposition.
PATIENTS AND METHODS
Patients. The Institutional Review Board of the Children's Hospital of Philadelphia and the Institutional Review Board of the University of Pennsylvania approved this research. Seven patients (four girls and three boys) participated in the study including four patients with Ewing's sarcoma, two patients with Hodgkin's disease, and one patient with nonHodgkin's lymphoma (Table 1) . Ages were between 11 years 7 months and 16 years 2 months at time of diagnosis (14.0 Ϯ 1.9; mean Ϯ SD). Their heights were between 144 and 187.6 cm (164 Ϯ 15.9 cm; mean Ϯ SD) and weights were between 36.9 and 137.6 kg (69 Ϯ 34.7 kg; mean Ϯ SD). All of the patients received etoposide at a dose of 100 mg/m 2 as a 1-h infusion daily for 5 days as part of an etoposide/ifosfamide-containing regimen. One patient received etoposide as the etoposide equivalent etopophos for 4 of the 5 days because of an allergic reaction (Table 1) . Serial blood samples were obtained at predose and over 24 h after treatment on days 1 and 5.
Biological Sample Collection and Handling. Blood samples were taken from each patient at selected time points before and after completion of the infusion on days 1 and 5. In a typical study, the blood samples were taken at time 0 (immediately before etoposide infusion), and 0.5 h (midway in the etoposide infusion), 1 h (immediately at the end of infusion), 1.25 h, 1.5 h, 2 h, 3 h, 4 h, 6 h, 8 h, 10 h, 12 h, and 24 h after the etoposide infusion was begun. The blood samples were kept on ice and centrifuged at 3000 rpm for 10 min at 10°C. Plasma was stored immediately in a Ϫ80°C freezer. To obtain proteinfree plasma, plasma (0.5 ml) was added to a Centrifree filter (Millipore) and centrifuged at 10°C for 60 min at 1900 ϫ g. The protein-free plasma samples were also stored at Ϫ80°C.
Assay of Study Samples. Etoposide and etoposide catechol were extracted from the plasma or protein-free plasma and analyzed using liquid chromatography/tandem mass spectrometry as described previously (31) . Teniposide, which is an analog of etoposide, was used as the internal standard. In summary, for the quantification of total etoposide and its catechol in plasma samples, 50 l of plasma (standard samples, quality control samples, or patient samples), 20 l teniposide solution (internal standard, 10 g ml Ϫ1 ), 20 l freshly made ascorbic acid solution (50 mM), and 260 l acetonitrile were added to an Eppendorf centrifuge tube. After vortex mixing for 5 min, the sample tubes were centrifuged in an Eppendorf 5415C centrifuge at 14,000 rpm for 5 min. The supernatant of each sample was transferred into another Eppendorf centrifuge tube and evaporated to dryness under a stream of nitrogen. The residues were reconstituted in 200 l of 34% acetonitrile in water (initial mobile phase for high-performance liquid chromatography gradient). The sample solutions were filtered through a Costar spin-X filter (2 m) and transferred to autosampler vials, and 20 l of each solution was injected into the high-performance liquid chromatography system. The procedure for the proteinfree fraction analysis was the same as for total plasma except that 200 l of protein-free plasma was used instead of 50 l of plasma, and the amount of acetonitrile was increased to 800 l. Reversed-phase chromatography was performed on a YMC (Wilmington, NC) octadecyl silane analytical column (150 ϫ 2.0 mm inside diameter; 3 m) using a Waters (Milford, MA) Alliance 2690 high-performance liquid chromatography system. The mobile phase consisted of 5 mM ammonium formate and 0.1% aqueous formic acid solution with 10% acetonitrile as A and 90% acetonitrile as B at a flow rate of 0.2 ml/min. Mass spectra were acquired on a Finnigan TSQ7000 triple-quadrupole mass spectrometer (Thermo Finnigan, San Jose, CA) equipped with an electrospray ionization source. The mass spectrometer was operated in the positive ionization mode, and nitrogen was used as both sheath gas (70 psi) and auxiliary gas (25 units). The source was maintained at 200°C and the needle potential at 4.5 kV. The multiplier voltage was set at 1500 V, and argon was used as the collision gas at 3.5 mTorr (1 Torr ϭ 133.3 Pa). The mass spectrometer was configured in the selected reaction monitoring mode with a transition of m/z 606 3 m/z 229 for etoposide, m/z 592 3 m/z 229 for etoposide catechol, and m/z 674 3 m/z 383 for teniposide (internal standard). The collision energy offset was set at Ϫ32 eV for both etoposide and teniposide, and Ϫ25 eV for etoposide catechol. The linear ranges for the standard curves were 0.2-100 g/ml for total etoposide analysis, 10 -5,000 g/ml for total catechol analysis, 25-15,000 ng/ml for free etoposide analysis, and 2.5-1,500 ng/ml for free catechol analysis. The data were analyzed by using LCQuan Ver 1.2. Quantification was achieved by plotting the peak area ratio of the analytes to the internal standard versus concentration followed by linear regression analysis with a weighting factor of 1/x 2 . The plasma or protein-free plasma quality controls for each analyte were prepared, stored, and assayed with the study samples. The standard curves were linear with R 2 Ն 0.997. The predicted concentrations of the quality control samples were between 94% and 108% of their nominal values. The intra-day and inter-day assay variability was Ͻ6.5%. The standard curve and quality control samples indicated that the assay method had good precision and accuracy, and that the analytes were stable under the storage and assay conditions. Pharmacokinetic Analysis. All of the modeling was conducted using the WinSAAM kinetic modeling software developed at NIH (32) . 5 A weighted least-squares approach was used to fit the total etoposide, total catechol, free etoposide, and free catechol simultaneously, leading to the direct estimates of the adjustable rate constants. For all of the data fitting, rate parameters were considered resolved when their fractional SDs were Ͻ0.3 (or 30%). No estimated parameters had a fractional SD Ͼ20%. Statistical analyses of pharmacokinetic parameters were conducted using STATA 7 software (STATA Corporation, College Station, TX). Using the (no constant) no Y intercept option in STATA 7, day 5 parameter values were regressed against the corresponding day 1 parameters. If the regression slope was significantly different from day 1, then the day 5 parameter value was deemed significantly different from the corresponding day 1 parameter.
RESULTS
A first order four-compartment model (Fig. 2 ) was used to fit the plasma concentration, and the protein-free plasma concentrations of etoposide and its catechol metabolite for each of the 7 patients. This model accounted for both elimination and metabolism. The distribution spaces of free etoposide and free etoposide catechol were assumed to be the same and constrained to be equal to the extracellular fluid volume, which is ϳ21% of bodyweight (Table 2 ; Ref. 33 ). This assumption provided the best fit to the data. The distribution spaces for protein-bound etoposide and etoposide catechol were also assumed to be the same, and were estimated to be 15.7 Ϯ 1.1 and 13.5 Ϯ 3.5% of bodyweight on days 1 and 5, respectively (Table 2) . Thus, the distribution volume of protein-bound etoposide and etoposide catechol is approximately three times the plasma volume (33) . Because plasma volume is ϳ5% of bodyweight, this indicates that approximately two-thirds of etoposide and its catechol are bound to proteins outside of the vascular space, perhaps to proteins on the vascular walls or to protein binding sites in well-vascularized tissue such as liver, spleen, and muscle.
The intercompartment rate constants for etoposide catechol were assumed to have the same values as the corresponding rate constants describing the movement of etoposide. A representative plasma concentration of total etoposide, total etoposide catechol, free etoposide, and free etoposide catechol concentration versus time curve is shown in Fig. 3 . The pharmacokinetic parameters obtained from WinSAAM modeling for total and free etoposide and etoposide catechol are summarized in Tables  2-4 . On the basis of the model shown in Fig. 2 , the distribution half-lives (t 1/2␣ ) for free etoposide ranged from 10.0 to 56.9 min on day 1, and from 9.2 to 92.0 min on day 5. For free etoposide catechol, the distribution half-lives (t 1/2␣ ) ranged from 10.1 to 54.5 min on day 1 and from 22.1 to 52.4 min on day 5. The elimination half-lives (t 1/2␤ ) for free etoposide ranged from 200 to 332 min on day 1 and from 86.3 to 481 min on day 5. For free etoposide catechol, the elimination half-lives (t 1/2␤ ) ranged from 80.7 to 410 min on day 1 and from 74.4 to 332 min on day 5. As shown in Table 4 , the mean maximum plasma concentration for total etoposide catechol (0.262 Ϯ 0.107 g/ml) on day 5 was higher (P Ͻ 0.05) than that for total etoposide catechol (0.114 Ϯ 0.028 g/ml) on day 1. Similarly, the mean free etoposide catechol concentration on day 5 (0.0186 Ϯ 0.0082 g/ml) was higher than on day 1 (0.0120 Ϯ 0.0091 g/ml).
The mean area under the plasma concentration-time curve (AUC) 24h for total etoposide (3358 Ϯ 968 g⅐min/ml) and free etoposide (156 Ϯ 55 g⅐min/ml) on day 5 were significantly (P Ͻ 0.05) less than those for total etoposide (3966 Ϯ 1268 g⅐min/ml) and free etoposide (207 Ϯ 54 g⅐min/ml) on day 1 (Table 3 ). In contrast, the mean AUC 24h for total etoposide catechol (105.4 Ϯ 49.1 g⅐min/ml) and free etoposide catechol (4.89 Ϯ 2.23 g⅐min/ml) on day 5 were much greater than the mean AUC 24h for total etoposide catechol (55.9 Ϯ 16.1 g.min/ ml) and free etoposide catechol (3.04 Ϯ 1.04 g⅐min/ml) on day 1 (Table 4) . Similar results were observed for the AUC 6h (Ta- Tables 2-4 ). However, the fractional rate constant K(0,1) for the elimination of etoposide (renal excretion and/or formation of other metabolites) was significantly greater (P Ͻ 0.05) on day 5 when compared with day 1 (Table 2) .
DISCUSSION
Etoposide disposition in pediatric populations has been studied extensively and is similar to that in adults (34 -36) . However, there are only a few studies on the disposition of its major metabolite, etoposide catechol, in either adults or children (37) (38) (39) . We have used a highly sensitive and specific liquid chromatography/ tandem mass spectrometry assay for the simultaneous determination of both the total and free fraction of etoposide and its catechol metabolite in plasma in a pediatric population. Using WinSAAM modeling, we have demonstrated that both the free and total (free ϩ noncovalently protein-bound) forms of the genotoxic catechol metabolite, but not etoposide, increased during multiple-day dosing in seven pediatric patients treated with etoposide for 5 days by conventional bolus i.v. dosing. In a prior study of adults receiving etoposide at myeloablative bolus 1-h doses of 600 mg/m 2 /day for 4 days before hematopoietic stem cell transplantation for the therapy of germ cell tumors, the concentration of the catechol metabolite was also observed to increase from the first day to the last day of treatment (40) . In a prior study of children receiving etoposide as a 2-h bolus dose of 300 mg/m 2 , etoposide and etoposide catechol disposition were measured on a single day (39) . The present study provides the first data on sequential, multiple-day etoposide catechol pharmacokinetics when etoposide was administered at conventional, nonmyeloablative doses in a pediatric population.
To begin elucidation of the mechanisms by which secondary leukemias occur after treatment with etoposide, it is important to fully understand the disposition of etoposide and its catechol metabolite in adults and children. In patients receiving etoposide for anticancer treatment, a substantial amount of plasma etoposide is noncovalently bound to plasma proteins with significant interpatient variation (41) . The unbound (protein-free) fraction of etoposide correlates more closely with both toxicity and efficacy than the total drug concentration (42) . Therefore, it is important to develop a rational pharmacokinetic model that is able to simultaneously determine the total and free fractions of etoposide and its catechol metabolite. On the basis of the WinSAAM modeling program, the best fit of the plasma and protein-free plasma concentration-time parameters was achieved by using a first-order four-compartment model shown in Fig. 2 . With the same topology as that was described previously (31, 39) , this model made it possible to simultaneously determine the pharmacokinetic parameters for total and free etoposide parent drug and its major catechol metabolite. The intercompartmental fractional transfer rates were not significantly different between day 1 and day 5. However, K(0,1), the fractional rate constant describing the elimination or removal of free etoposide, was significantly (P Ͻ 0.05) increased on day 5. We speculate that this might be a reflection of either an increase in excretion of etoposide or an increase in the rate of etoposide metabolism.
The mean maximum concentration for total etoposide catechol on day 5 (0.262 Ϯ 0.107 g/ml) was higher than on day 1 (0.114 Ϯ 0.028 g/ml; Table 4 ). The same trend was observed for free etoposide catechol (Table 4 ). These results suggest that exposure to the catechol metabolite increases in pediatric pa- tients after multiple-day conventional bolus dosing. Among the patients studied, the inter-individual variability in maximum concentration was small and there were no obvious outliers. The mean AUC 6h and AUC 24h for total etoposide catechol on day 5 were greater than on day 1 (Table 4 , Fig. 4) . Similar results were observed for free etoposide catechol, the AUC 6h and AUC 24h for which also were significantly higher on day 5 than on day 1 (Table 4 , Fig. 4) . These results indicate that the patients were exposed to a higher concentration of etoposide catechol (total and free) on day 5 than on day 1. In contrast, the AUC 24h of total and free etoposide on day 5 were significantly less than on day 1 ( Table 3 , Fig. 5 ). There are four possible mechanisms which could account for or contribute to the elevated concentrations and AUCs of total and free etoposide catechol observed on day 5:
1. Increased formation of etoposide catechol. On day 5, the fractional rate of formation of etoposide catechol K(3,1), 0.00744 Ϯ 0.00710 was substantially although not statistically significantly greater than 0.00234 Ϯ 0.00188 on day 1 ( Table 2 ). In addition, the estimated % conversion of etoposide to etoposide catechol [K(3,1)/(K(0,1) ϩ K(3,1)] was 14.4 Ϯ 22.2 on day 5 compared with 3.6 Ϯ 3.0 on day 1 ( Table 2) .
2. Decreased elimination of etoposide catechol. The mean fractional elimination rate of etoposide catechol on day 5 (0.265 Ϯ 0.290), although not statistically significant (P Ͼ 0.05), was numerically higher than that on day 1 (0.153 Ϯ 0.111 min -1 ), so this is unlikely to be the explanation. 3. Decreased volume of distribution of etoposide catechol. From Table 2 , the volume of distribution for free etoposide catechol is unchanged from day 1 to day 5 and, for proteinbound etoposide catechol, there is only a slight (nonsignificant) decrease in volume of distribution from 15.7 Ϯ 1.1% of body weight on day 1 to 13.5 Ϯ 3.5% of body weight on day 5. We speculate that this nonsignificant decrease in apparent volume of distribution of protein-bound etoposide and catechol may signify a slight increase in the concentration of catechol-binding proteins within plasma.
4. Accumulation of etoposide catechol from the dose of the previous day. The amount of etoposide catechol remaining in the body 24 h after a dose of etoposide depends upon the rate at which etoposide catechol is formed and the rate at which etoposide catechol is eliminated from the body. There is much individual variation in these two processes (Tables 2-6) , and some subjects have relatively slow clearance of etoposide catechol. However, simulation analysis using kinetic parameters from day 1 indicates that accumulation of etoposide catechol in plasma due to the dosing of the previous day with etoposide accounts for a negligible amount of the increase in plasma catechol concentrations observed on day 5.
From our pharmacokinetic analysis, no single mechanism could be statistically identified as being a cause for the elevated concentrations and AUCs of total and free etoposide catechol observed on day 5. However, our results are consistent with the possibility that a combination of increased rate of formation of etoposide catechol and decreased volume of distribution of etoposide catechol could together be responsible for the elevated concentrations and AUCs of total and free etoposide catechol observed on day 5.
Etoposide catechol is formed primarily through CYP3A4 metabolism (10) . Our results are consistent with the possibility that during multiple-day dosing the enzyme is induced, resulting in increased etoposide metabolism, with concomitant increased formation of the catechol metabolite. In fact a recent study using a mouse model system has reported that etoposide can induce pregnane X receptor-mediated CYP3A4 transcription (43) . However, little is known about the relative importance of CYP3A5 in the metabolism of etoposide and it is also conceivable that induction of this enzyme (44) could contribute to the increased formation of the catechol metabolite. Studies are currently in progress to distinguish these two possibilities. Another factor that may have influenced the pharmacokinetic profiles in this study was the concurrent administration of ifosfamide as part of the multiple-agent regimen. No changes in the maximum concentration, mean AUC 6h , or AUC 24h were observed for free or total etoposide. Ifosfamide is known to induce CYP3A4 in primary hepatocytes maintained in culture (45) . Therefore, it is possible that concurrent ifosfamide administration may have been of relevance to the increase in these parameters for free and total etoposide catechol observed between days 1 and 5. To investigate this latter possibility it would be necessary to perform the study with etoposide alone. However, because etoposide generally is used in multiagent regimens in patients, human hepatocytes in culture could be used to determine whether etoposide alone is able to induce its own metabolism.
Current approaches including chemotherapy and hematopoietic stem cell transplantation offer little hope for patients diagnosed with leukemia secondary to epipodophyllotoxin treatment. These leukemias are clinically aggressive and reported long-term survival rates are only approximately 10 -20% (46, 47) . The absence of PCR-detectable leukemia-associated chromosomal translocations in the bone marrow before the start of chemotherapy and the association of DNA topoisomerase II inhibitors but not other cytotoxic chemotherapeutic agents with leukemias with characteristic balanced translocations have suggested that DNA topoisomerase II inhibitors cause the translocations, which are essential aberrations in this form of leukemia (48, 49) . One of the patients in this study has already been affected with leukemia as a treatment complication. Whereas this study demonstrates that in the pediatric population conventional multiple-day bolus dosing of etoposide is associated with increased formation of the genotoxic catechol metabolite from the first day to the last day of treatment, the risk of leukemia (approximately 2-3%) associated with such regimens (6), nonetheless, is less than that observed in the past with once weekly or twice weekly dosing (7) . Safe etoposide regimens without any risk of leukemia are yet to be achieved. Studies of genetic 
